Mesoblast Gains as FDA Clears Ryoncil Study FDA cleared Mesoblast study of Ryoncil on Apr 8, 2026; Duchenne affects ~1 in 3,500–5,000 male births and ~15,000–20,000 people in the U.S., creating a sizable addressable cohort.

Mesoblast Gains as FDA Clears Ryoncil Study: FDA cleared Mesoblast study of Ryoncil on Apr 8, 2026; Duchenne affects ~1 in 3,500–5,000 male births and ~15,000–20,000 people in the U.S., creating a… 👈 Read full analysis #Mesoblast #FDAApproval #Ryoncil #DuchenneMuscularDystrophy #ClinicalTrials

Mesoblast stock soars after reporting first Ryoncil sales Investing.com -- Mesoblast Ltd (NASDAQ:MESO) stock surged 25% after the company reported its first quarter of sales for its newly approved drug Ryoncil, which generated $13.2 million in gross revenue. The cellular medicines company launched Ryoncil on March 28, 2025, following FDA approval for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children. Ryoncil is the first and only FDA-approved mesenchymal stromal cell product in the United States. In addition to product sales, Mesoblast reported $1.6 million in royalty revenue from its Japanese licensee for TEMCELL HS Inj. The company ended the quarter with a strong cash position of $162 million as of June 30. The commercial rollout is progressing steadily, with more than 25 transplant centers onboarded since launch. Mesoblast expects to complete onboarding across all 45 priority transplant centers this quarter, which account for approximately 80% of U.S. pediatric transplants. Insurance coverage for Ryoncil continues to expand, now covering over 250 million U.S. lives through commercial and government payers. Notably, mandatory fee-for-service Medicaid coverage became effective July 1 in all U.S. states. The company has established patient access programs through its MyMesoblast hub to ensure treatment accessibility. Ryoncil also received seven years of orphan-drug exclusivity from the FDA, providing market protection through 2032, in addition to biologic exclusivity preventing biosimilar entry until December 2036. Mesoblast is working to expand Ryoncil’s label to include adults with SR-aGvHD and continues development of its other pipeline products for chronic inflammatory heart failure and low back pain. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if MESO is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #Mesoblast #Ryoncil #Investing #StockMarket #Pharmaceuticals

MSB surged today, up 34.64% on the day

This follows the company’s announcement of US$13.2 million revenue from the commercial sales of Ryoncil.

Ryoncil is the first mesenchymal stromal cell product in the United States

buff.ly/DoUGrNm

#MSB #mesoblast #ASX #EconSky #FinSky 📈

Mesoblast Advances U.S. Launch of Cell Therapy as FDA Reviews Two Key Programs Mesoblast (NASDAQ: MESO), a company developing advanced cell-based medicines, is gaining traction in the U.S. healthcare market with two major updates. First, i

#MESO Moves Forward in U.S. Cell Therapy Launch
Mesoblast is making strides with two key FDA-reviewed programs, marking a major step toward bringing its innovative cellular therapies to patients in the U.S.
#Mesoblast
prismmarketview.com/mesoblast-ad...

#Mesoblast (ASX:MSB) fue el valor con mejor rendimiento, subiendo un 8.06% para llegar a 3.35, alcanzando su mayor nivel en 3 años. #Appen Ltd y #StBarbara Ltd también destacaron con avances de más del 6% y 4%, respectivamente. #RendimientoBursátil #InversionesAustralia

El mercado de Australia cerró con ganancias este jueves, impulsado por los sectores de energía, recursos, y metal y minería. El #S&PASX200 subió un 0.52%, con #Mesoblast liderando la sesión con un avance del 8.06%. #MercadoAustralia #Inversiones

ISCT Celebrates Historic FDA Approval of RYONCIL for Pediatric GvHD Treatment in the U.S. The landmark FDA approval of RYONCIL for treating steroid-refractory acute GvHD in children marks a significant advance in MSC therapies, according to ISCT.

ISCT Celebrates Historic FDA Approval of RYONCIL for Pediatric GvHD Treatment in the U.S. #United_States #Vancouver #FDA #Ryoncil #Mesoblast

US FDA Approves Mesoblast’s Cell Therapy for Graft-Versus-Host Disease the U.S. Food and Drug Administration approved Mesoblast's (NASDAQ: MESO) cell therapy for treating a type of complication that occurs after a stem cell or

US FDA Approves Mesoblast’s Cell Therapy for Graft-Versus-Host Disease

abbonews.com/healthcare/u...

#Mesoblast #Wallstreet #NYSE #NASDAQ #Stocks #StockNews #StockMarketNews #news #newsalert #BusinessNews